Valerio Therapeutics Société anonyme (C4X.F)

0,0922 -0,0088 (-8,71%) A partir del 09:05AM CEST. Mercado abierto.

Valerio Therapeutics Société anonyme

49, boulevard du Général Martial Valin
Paris 75015
France
33 1 70 38 33 99
https://valeriotx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 19

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Shefali Agarwal M.D., MPH	President, CEO & Chairwoman	N/A	N/A	1973
Ms. Joyce Carey	Executive Director of Finance and Head of FP&A	N/A	N/A	N/A
Ms. Robin Sutherland	VP & Global Head of Human Resources	N/A	N/A	N/A
Mr. Michel Forest	Chief Pharmacist & Quality Assurance Director	N/A	N/A	N/A
Ms. Huiping Jiang	Senior Vice President of Regulatory Affairs & Quality Assurance	N/A	N/A	N/A
Mr. Wael Jdey Ph.D.	Head of Preclinical	N/A	N/A	N/A
Dr. Donna Cabral-Lilly Ph.D.	VP & Head of CMC	N/A	N/A	N/A
Ms. Pam Slatcher	Head of Global PV	N/A	N/A	N/A

Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops AsiDNA, which is in Phase 1b/2 trial in combination with the PARP inhibitor Olaparib to evaluate safety in patients with epithelial ovarian cancer, breast cancer, and metastatic castration-resistant prostate cancer. It also develops Revocan that is in Phase 1b/2 trial to evaluate the addition of AsiDNA to combat PARP inhibitor resistance in second-line maintenance treatment of recurrent ovarian cancer, as well as in phase 1b/2 trial evaluating AsiDNA in combination with radiotherapy in recurrent highgrade glioma in children. In addition, it is developing VIO-01, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, a chemistry platform for building new molecules, which include OX400, a decoy DNA platform. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. The company was founded in 1997 and is headquartered in Paris, France.

Gobierno corporativo

El ISS Governance QualityScore de Valerio Therapeutics Société anonyme, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.